We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Obesity Candidate, PSN602

News   Jun 24, 2008

 
OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Obesity Candidate, PSN602
 
 
 

RELATED ARTICLES

Infrared to Visible Light: A Novel Route to Photodynamic Therapy & Drug Development

News

Researchers have succeeded in developing a chemical process to absorb infrared light and re-emit it as visible energy, allowing innocuous radiation to penetrate living tissue and other materials without the damage caused by high-intensity light exposure.

READ MORE

Targeted Photodynamic Therapy Stops Tumor Growth in 70% of Mice

News

A team of scientists has experimentally proved the effectiveness of the formerly suggested "light" method in oncotherapy. In a series of laboratory preclinical tests, the tumor growth stopped in 70% of mice.

READ MORE

‘Shortcut’ Transforms Terpene Biosynthesis in E. Coli

News

Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE